Prion diseases share common features of neurodegenerative disorders, infectious diseases and pathologies linked to misfolded proteins. Whether these aspects are independently and fortuitously present in prion diseases or are somewhat linked together remains unsettled, but the contribution of genomic, proteomic, metabolomic and spectroscopic techniques might give insights into this puzzle, and likely give hope for therapy to patients. Although the prion protein gene (PRNP) governs most of the clinical and pathological features of prion diseases and plays a pivotal role in determining host susceptibility, there are still many uncertainties and unknown risk factors that need to be clarified and identified. Several genes, other than PRNP, have recently been found to be associated with a risk of developing sporadic or variant Creutzfeldt-Jakob disease, but these novel data have been produced in a relatively small number of patients and controls and, therefore, need further confirmation. The same criticism applies to the identification of the over 20 new cerebrospinal fluid or plasma markers of disease. Some of these markers seem related to the massive brain damage that occurs, rather than being specific to prion infection. Nevertheless, genomic and post-genomic approaches have shown that these techniques are very powerful, and the best way to overcome the scantiness of samples would be to encourage strong collaboration between different centers of excellence in prion diseases. In this review, we describe the most recent and outstanding advances offered by genomics and post-genomics analyses in the field of human prion diseases.
other neurodegenerative disorders such as AD, prion diseases are likely monogenic. Other rare genetic forms of TSEs are fatal familial insomnia (FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS). Both sporadic and genetic prion disorders are transmissible to a wide range of laboratory animals (rodents, felines, and non-human primates) by the injection of crude brain homogenates. Depending upon the host, the type of inoculum, and the route of inoculation, the lag period between the time of injection and the development of clinical signs may last for weeks, months or years [8-10]. Around one-third into this asymptomatic period, the host starts producing PrP\textsuperscript{TSE} using its own PrP\textsuperscript{C} as a substrate. At the end of the incubation period the host develops clinical, behavioral, and neurological signs, and finally dies, usually after a few weeks of disease. However, after prion infection, mice with ablated prion protein gene (knock-out mice) do not produce PrP\textsuperscript{TSE} or clinical signs of disease, confirming the pivotal role of PrP\textsuperscript{C} in the pathogenesis of prion disorders [11]. In experimental prion models, treatment with a variety of compounds during the asymptomatic phase of disease delays the formation of PrP\textsuperscript{TSE} and the appearance of clinical signs [12]. In some cases, animals do not even develop disease [12]. However, there is virtually no beneficial effect if the treatment is started after the appearance of clinical signs, suggesting that the only possible approach in humans is prevention rather than therapy [13]. Naturally, prion diseases occur also in sheep and goats (scrapie disease), in cattle (bovine spongiform encephalopathy (BSE), and some very rare variants), and in cervids (chronic wasting disease (CWD)) [2]. A BSE epidemic, sustained by feeding cows with infected rendered meat, has produced a serious worldwide economic and health problem. Thousands of cattle have been killed in Europe and elsewhere to further prevent the rise of the epidemic and the possibility that BSE would transmit to humans. Despite these efforts, however, transmission of BSE to humans occurred in the 1990s and approximately 200 people, mostly in their 20s, died of a novel prion disease (variant CJD) [14]. Patients with variant CJD were probably infected via contaminated food in the late 1980s or early 1990s, but it is still unknown how many individuals are currently silently incubating the disease [15]. Occasionally, transmission of prion diseases occurs from man to man via improperly decontaminated surgical instruments, use of biological products taken from cadaveric human tissues [16], blood transfusion, or possibly plasmaderived products (so far these two modes of transmission have occurred only for variant CJD) [17,18].

Genetic analyses in human prion diseases

In humans, the PRNP gene is the only strong factor that determines both susceptibility and phenotypes of prion diseases. This gene presents several point or insert mutations that are responsible for the appearance of familial forms of prion diseases, and often each specific mutation is associated with a specific clinico-pathological phenotype [19]. The most striking example is the mutation at codon 178 (substitution of the aspartic acid with asparagine), which gives rise to two different prion diseases depending on whether the mutation co-segregates with methionine (FFI) or valine (genetic CJD) in the polymorphic codon 129. On the other hand, there is also evidence that within the same family, mutated carriers either develop different clinical phenotypes [20,21], develop disease at different ages, or do not develop disease at all [5]. These findings suggest that some other factors are involved in determining susceptibility to the disease [22], but no specific genomic studies have so far been conducted to exploit the possible involvement of other genes. The only exception is the finding that in a large kindred of GSS-affected patients with the proline to leucine mutation at codon 102 of the PRNP gene, apolipoprotein E4 (ApoE4) carriers have a delay in the age of onset of approximately 10 years without, however, any influence on the clinico-phenotype of the disease [21]. Whether ApoE4 influences age at onset in other forms of genetic prion diseases remains to be determined.

The methionine/valine polymorphic site of the PRNP gene also influences susceptibility to sporadic, iatrogenic and variant CJD. Approximately 60% of sporadic and 100% of variant CJD patients are methionine homozygous, compared to 40% of Caucasian populations, suggesting that there is a genetic predisposition even in the non-hereditary forms of prion diseases [4]. Sporadic CJD is not a single entity and different subtypes show clinical and neuropathological features [19]; some of them, such as disease survival, are partially determined by the polymorphic codon 129 but other factors might be involved in determining the rate of susceptibility, the age of onset, the clinical manifestations and, finally, disease duration [23]. Epidemiological and case-control studies have failed to identify convincing risk factors [24,25] and though it is still theoretically possible that as-yet unidentified environmental events may contribute to the development of the disease, it is likely that other genes are involved in its pathogenesis.

Genomic findings in human prion diseases

The major host player in controlling susceptibility to prion diseases is the PRNP gene. This was clearly shown in the pre-prion era by the pivotal genetic work carried out by Alan Dickinson and colleagues [26], who called the prion protein gene in mice the s\textsuperscript{inc} gene (after scrapie incubation period) and postulated that other genes would likely be involved in the pathogenesis of experimental scrapie [27]. The involvement of other genes has been subsequently confirmed in different models of scrapie-infected mice [28] but, until recently, there have been no data for human prion diseases. In this respect, an interesting genome-wide study of genetic risk in a human prion disease was recently performed by Mead and colleagues [29] in a relatively large cohort of
patients with various forms of prion diseases (variant, sporadic, iatrogenic CJD and historical kuru patients [30]) in comparison with healthy British and South Fore (for kuru) people. Genomic DNA was mostly extracted from peripheral blood, though some samples were extracted from brain tissue. The major result of this study is the confirmation that the risk of developing prion diseases is strongly associated with the polymorphic codon 129 of the PRNP gene. The authors also found single nucleotide polymorphisms (SNPs) contributing to disease risk in the intron of PRNP, upstream of the gene RARB, which encodes the retinoic acid receptor-β protein, and upstream of the gene STMN2, which encodes SCG10/stathmin-like 2, a neuronal growth-associated protein. Genetic risk factors for CJD have previously been identified upstream and downstream of PRNP [31,32], while retinoic acid has been shown to regulate the expression of the prion protein in cell cultures [33], and SCG10 to regulate microtubule stability in neuronal cells, which, in turn, might potentially modulate prion neurotoxicity [34]. It is therefore conceivable that a potential deregulation of RARB and STMN2 might be involved in the pathogenesis of prion diseases, and hence lead to an increased susceptibility of variant or iatrogenic CJD from exogenous exposure. However, the authors [29] could not link the presence of SNPs in the upstream regions of RARB and STMN2 to a modification of their expression and, since these genes are not expressed in blood cells, their products cannot be used as possible markers for prion diseases. In two other studies, the same group [35,36] reported two other genes (SPRN and HECTD2) found to be associated with risk of sporadic and variant CJD. SPRN was identified by comparative gene analysis [37]; it encodes Shado (Sho, shadow of prion protein), a highly conserved protein that has possible functional links with the prion protein [38], and different genetic variants have been associated with risk for either variant or sporadic CJD [35]. HECTD2 encodes an E3 ubiquitin ligase involved in regulating the incubation time of scrapie-infected mice [36], and a single SNP, located in the intron of the gene, was significantly over-represented in both variant and sporadic CJD [36]. Moreover, a high level of HECTD2 mRNA expression seems to be linked with variant CJD in the UK population [36]. These studies are of great interest but it is somewhat surprising that upregulation of these genes was not found by the same group in their genome-wide association study for the identification of CJD risk-associated factors [29].

In another study, Xiang and colleagues [39] applied global gene expression microarray technology to the frontal cortex of 15 patients with sporadic CJD and compared the global gene expression with frontal cortical samples of patients dying of unrelated diseases without clinical signs of neurological diseases, and with unremarkable neuropathology. They found several upregulated (n = 79) and downregulated (n = 275) genes in sporadic CJD compared to controls. Some of the upregulated genes are clearly linked to the pathological process of degeneration (for example, those encoding GFAP and S100; the latter protein is also increased in cerebrospinal fluid (CSF) and plasma of CJD patients), or to the immune and inflammatory responses that clearly occur in prion diseases [40]. The upregulation of genes encoding cysteine-rich intracellular proteins with a high capacity to bind to zinc and copper (that is, metallothionein-1 and -2) has also been previously reported in human prion diseases [41]. Reduced expression was observed in genes (SNAP-25 and synaptophysin) that are involved in synaptic function and plasticity and that were previously found at decreased levels in the cerebral cortex of CJD patients [42]. This work is of great interest in terms of identifying genes that are involved in the pathological process of prion diseases, but it is necessary to validate these results by using control patients with other neurodegenerative disorders, in order to identify prion-specific genes rather than hundreds of genes that are clearly deregulated during massive brain damage.

**Proteomics and metabolomics in the search for markers of prion infection**

The only marker that is included in the World Health Organization (WHO) diagnostic criteria for sporadic CJD is the 14-3-3 protein in CSF. This marker, alone or in combination with other neuron-specific, brain-derived proteins (neuron-specific enolase, Tau and phosphorylated Tau, and the astrocytic protein S100b), has been extensively evaluated and validated in all forms of human prion diseases (for comprehensive reports see [43-45]). However, these tests only reach high levels of sensitivity and specificity if a patient is likely, on clinical grounds, to have sporadic CJD [44]; it is thus important to maintain interest in and focus resources on finding novel and more specific markers for prion diseases.

In Table 1, we report novel markers that have been identified in the CSF or plasma of patients with various forms of prion diseases. Data are not always comparable, due to the small number of prion patients and to the choice of controls, often taken from healthy individuals without including patients with different neurodegenerative disorders, rather than being due to the techniques used. These critical aspects were taken into serious consideration by Brechlin and co-workers [46], who applied stringent criteria and appropriate neurological controls for the identification of five possible markers for sporadic CJD using two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Interestingly, three of these protein spots were subsequently identified as well-known markers for prion diseases (14-3-3, two spots, and neuron-specific enolase) and the fourth as lactate dehydrogenase, previously reported in sporadic CJD by the same group [47].

The other interesting finding in these studies is that variant and sporadic CJD may present some different biochemical...
| Marker          | Cellular function                                                                 | Relative levels in human prion disease compared to controls | Reference | Notes                                                                 |
|----------------|----------------------------------------------------------------------------------|-------------------------------------------------------------|-----------|----------------------------------------------------------------------|
| α1-ACT         | Serine proteinase inhibitor                                                       | ↑sCJD, ↔sCJD                                               | [54]      | Elevated in urine of sCJD and in plasma and CSF of AD               |
|                |                                                                                  | ↑sCJD                                                      | NT [63]   |                                                                      |
| α-Tocopherol   | Major lipophilic antioxidant                                                     | ↓sCJD, ↔sCJD                                             | [64]      |                                                                      |
| Apolipoprotein | Components of high density lipoprotein in plasma. Participate in PrP clustering and sequestration | ↑sCJD, ↔sCJD, ↓sCJD                                      | [54, 63]  |                                                                      |
|                |                                                                                  | ↑vCJD compared to sCJD                                    | NT [66]   |                                                                      |
|                |                                                                                  | ↑sCJD (A1 and A4)                                         | NT [63]   |                                                                      |
|                |                                                                                  | ↓sCJD (Apo-J, Clusterin)                                  | NT [63]   |                                                                      |
| Ascorbate      | Major hydrophilic antioxidant                                                   | ↓sCJD, ↓sCJD                                             | [54, 64]  |                                                                      |
| C-reactive protein | Markers for inflammation or tissue injury                                   | ↑sCJD, ↑sCJD                                             | NT [54]   |                                                                      |
| Cystatin C     | A cysteine proteinase inhibitor, mostly synthesized in the CSF; it is also localized in glial cells and neurons | ↑CJD (not specified)                                      | NT [67]   |                                                                      |
|                |                                                                                  | ↑sCJD, ↔sCJD                                             | [68]      | Gene is upregulated in the brain of sCJD; reported normal in AD patients |
|                |                                                                                  | ↑sCJD, ↑sCJD                                             | [63]      |                                                                      |
|                |                                                                                  | ↑sCJD, ↑sCJD                                             | NT [54]   |                                                                      |
| F2-isoprostanes | Markers of lipid peroxidation and oxidative stress in vivo                    | ↑sCJD, ↑S2CJD                                             | NT [48]   |                                                                      |
| Gelsolin       | Regulator of actin filament assembly                                             | ↑sCJD, ↓sCJD                                             | NT [49]   |                                                                      |
| H-FABP         | Belonging to a family of small, highly conserved, cytosolic proteins involved in fatty acid transport and metabolism | ↑sCJD, ↑sCJD, ↑sCJD                                      | [55]      | CSF of CJD taken post-mortem while in controls taken from living individuals; plasma levels do not differ between CJD and AD |
|                |                                                                                  | ↑sCJD, ↑vCJD                                             | NT [56]   |                                                                      |
|                |                                                                                  | ↑sCJD, ↑sCJD                                             | NT [56]   |                                                                      |
|                |                                                                                  | ↑sCJD, ↑sCJD                                             | [56]      |                                                                      |
| Hp2-α haptoglobin | Binds hemoglobin for physiological degradation                                   | ↑sCJD, NT [63]                                           | NT [63]   |                                                                      |
| Interleukin 1β | Pro-inflammatory cytokine, involved in immune response                           | ↑sCJD, ↑vCJD                                             | NT [70]   |                                                                      |
| Interleukin 4 and 10 | Anti-inflammatory cytokine                                                           | ↑sCJD, NT [71]                                         | NT [71]   |                                                                      |
| Interleukin 6  | Markers for inflammation or tissue injury                                        | NT, ↔sCJD                                                | NT [67]   |                                                                      |
| Interleukin 8  | Chemokine with immunoreactive s propertie                                         | ↑sCJD, NT [71]                                           | NT [71]   | Increased in AD, but at a lower level than CJD                      |
| Lactic acid    | End-product of anaerobic glycolysis                                               | ↑sCJD, NT [72]                                           | NT [72]   | Produced by LDH action on pyruvate                                |
| LDH            | Catalyzes the interconversion between pyruvate and lactic acid                   | ↑sCJD, NT [46, 47]                                       | NT [46, 47]|                                                                      |

Continued overleaf
markers (ApoE [50], P2-isoprostanes [48,49], uric acid [50]; Table 1), which might reflect different molecular processes in these diseases. This observation is in line with what was observed in the recent genomic studies, where different genes or variants of genes are related to one or the other form.

Proteomic approaches have also been extensively used to investigate the pathogenesis of prion diseases, but the majority of these studies, even those conducted with experimental animal models, were performed in post-mortem brain tissues, and it is therefore difficult to determine whether deregulation of identified proteins is a late result of neurodegeneration or specifically linked to prion-specific lesions. However, the finding that levels of proteins known to interact with Ca$^{2+}$, or whose function is regulated by Ca$^{2+}$, are significantly modified in the brains of affected animals [51-53] clearly deserves further investigation.

By analogy with other neurodegenerative disorders such as AD, the presence of oxidative stress has been investigated in different tissues, including CSF and blood from prion-affected individuals (Table 1). These studies have shown the activation of several pro- and anti-oxidative mechanisms in prion disorders, but these pathways are shared by other neurological disorders and cannot be regarded as prion-specific biomarkers. Besides oxidative mechanisms, an atypical inflammatory response is activated in the central nervous system of prion-infected individuals, and consequently a number of (pro)inflammatory mediators are deregulated in the CSF of patients with prion diseases (Table 1) [40]. These mechanisms, however, are often common to other neurodegenerative disorders and may be of limited value as specific prion-disease markers.

Very few studies have been conducted for the identification of markers in human blood or urine [54-57]. Among them, the heart-fatty acid-binding protein (H-FABP) has been found, by two different groups, to be increased in both CSF and plasma of individuals with sporadic and variant CJD [55,56]. Blood manganese is another promising marker
since its concentration is higher in the blood of individuals with sporadic CJD than in patients with other neurodegenerative disorders [57].

**Spectroscopic and imaging techniques**

Proton magnetic resonance spectroscopy (1H-MRS) has been extensively applied for detecting metabolic alterations in the brain of prion-diseased patients [58,59]. These studies, though conducted in a very limited number of patients, are very consistent and always confirm a reduction of N-acetyl-aspartate (NAA; a marker of neuronal loss), concomitant increase of myo-inositol (MI; an astrocyte marker), and a reduction of the NAA:creatine ratio. Interestingly, in a single asymptomatic carrier of the pathogenic mutation P102L (linked to GSS), Waldman and co-workers found an increase of MI with no variation of NAA [60], suggesting that gliosis starts before massive neuronal loss, and that this compound may be a valid candidate as a preclinical marker of prion diseases.

The novel technology of atomic dielectric resonance spectroscopy (ADRS [61]) has been demonstrated to discriminate between blood of CJD patients and that of neurological and healthy controls, as well as between sporadic and variant CJD patients, with 100% specificity and sensitivity. Though these data were blind-validated in only ten patients (four variant CJD, three sporadic CJD, and three non-neurological controls), they confirm data that have been previously reported for the sera of scrapie-infected rodents investigated by Fourier transform-infrared (FT-IR) spectroscopy [62]. It would therefore be interesting to extend the result obtained by Fagge and co-workers [61] to a larger number of patients and possibly to asymptomatic PRNP mutated carriers, to determine whether the ADRS signal might be useful to identify prion disease during the pre- or subclinical phase.

**Conclusions**

Sporadic and variant CJD and most of the related prion disorders are relatively easy to diagnose based upon clinical signs and available instrumental and laboratory tools, which include electroencephalography, brain-imaging techniques and detection of the marker 14-3-3 in the CSF, alone or in combination with other neuron-specific, brain-derived proteins. Thus, in clinical practice the search for other markers in diseased patients is of limited extra value. What is missing, however, is highly predictive markers in easily accessible tissues, such as CSF, blood or urine, that would be able to recognize infected but yet clinically healthy individuals. The best candidate marker would be PrP\textsuperscript{TSE}, but this pathological isoform is either not present or difficult to identify in body fluids. Markers of prion infectivity are also essential for the screening of blood for transfusion and for plasma or urine donations before their use for production of medicinal products. As a result, resources have been devoted to the development of markers of infection aimed at screening of animal- and human-derived biological products, improving diagnostic tools to identify infected individuals in their preclinical stage of disease, and controlling disease progression. These two latter goals would most likely enhance the possibility of developing preclinical therapy in prion diseases and having objective tools for measuring the effectiveness of potential treatments.

Two other issues in prion diseases that might be solved by the complementary approaches of genomics, proteomics and metabolomics are the search for genes and proteins, other than PRNP and the encoded prion protein, that might increase the susceptibility of developing prion disease. This would apply to the inherited forms of prion diseases, as outlined above, to sporadic CJD, and, of particular importance, to determining why a widespread population exposure to BSE infection has resulted in only approximately 200 cases of variant CJD. Another issue is the identification of genes that influence disease duration. This topic is clearly important for understanding the pathogenesis of prion diseases and might eventually lead to the development of novel anti-prion compounds, but it is also needed in clinical practice to better formulate the prognosis of patients and, finally, to monitor the efficacy of potential drugs in therapeutic trials. The PRNP gene plays an important role in determining survival, as well as the conformational type of PrP\textsuperscript{TSE} that accumulates in the brain [23]. However, these factors do not fully explain the great variability observed in human prion diseases and it is therefore likely that other genetic or environmental determinants are involved. Genomic studies are not yet available on this issue, but their application will certainly be of great utility to add other pieces to the prion puzzle.

**Abbreviations**

AD, Alzheimer's disease; ADRS, atomic dielectric resonance spectroscopy; ApoE\textsubscript{4}, apolipoprotein E\textsubscript{4}; BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; CWD, chronic wasting disease; 2D-DIGE, two-dimensional differential gel electrophoresis; FFI, fatal familial insomnia; FT-IR, Fourier transform-infrared; GSS, Gerstmann-Sträussler-Scheinker syndrome; H-FABP, heart-fatty acid-binding protein; \textsuperscript{1}H-MRS, proton magnetic resonance spectroscopy; MALDI, matrix-assisted laser desorption ionization; MI, myo-inositol; NAA, N-acetyl-aspartate; PRNP, prion protein gene; PrP\textsuperscript{c}, cellular prion protein; PrP\textsuperscript{TSE}, pathological isoform of PrP; SNP, single nucleotide polymorphism; TSE, transmissible spongiform encephalopathy; WHO, World Health Organization.

**Competing interests**

The authors declare that they have no competing interests.
Authors’ contributions
All the authors have actively contributed to the preparation of this work.

Acknowledgements
This work has been partly granted by the EU Specific Target project ‘Prionscreen’ (HSPPA-CT-2007-044438), by the Italian Ministry of Health ‘Progetto Strategico 1%2001’, by the ISS-NIH research program on ‘Rare Diseases 2006’, and by the ISS grant ‘Ricerca Corrente 2006–2008’. Special thanks to Dr Alessandra Garozzo and Mr Marco Del Re for editorial assistance.

References
1. Stewart LA, Rydzewska LH, Keogh GF, Knight RS: Systematic review of therapeutic interventions in human prion disease. Neurology 2008, 70:1272-1281.
2. Aguzzi A, Sigurdson C, Heikenwalder M: Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008, 3:11-40.
3. Caughey B, Lansbury PT: Prion fold, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26:267-298.
4. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug M, Trettel T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel J-P, Poss K, Kretzschmar H, Rietveld I, Mitrova E, de Pedro-Cuesta J, Martinez-Martin P, Glatzel M, Pocchiari A, Cooper S, Mackenzie J, van Dijl CM, Will RG, Zerr I: Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia and Canada. Neurology 2005, 64:1586-1591.
5. Ladogana A, Puopolo M, Pollegi A, Almoini S, Melini V, Equestre M, Pocchiari M: High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005, 64:1592-1597.
6. Capellari S, Pia R, Portelli P, Avoni P, Casadei GP, Bini C, Baruzzi A, Lugaresi E, Pocchiari M, Gambetti P, Montagna P: Sporadic fatal insomnia in a familial insomnial pedigree. Neurology 2008, 70:884-885.
7. Webb TEF, Pal S, Siddique D, Heaney DC, Lichens J, Mawdsley J, JDF, Joiner S, Beck J, Wroe SJ, Stevenson V, Brandner S, Mead S, Collinge J: First report of Creutzfeldt-Jakob disease occurring in 2 siblings explained by PRNP mutation. J Neuropath Exp Neurol 2008, 67:939-941.
8. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Silmna MP, Bacote A, Goldfarb LG, Gajdusek DC: Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Acta Neurol Scand 1995, 91:313-329.
9. Tateishi J, Kitamura T, Hooe MZ, Furukawa H: Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents. Neurology 1996, 46:532-537.
10. Bruce ME, Williams RG, Ironside JW, McConnell I, Drummond D, Sutcliffe T, Giulivi A, Alperovitch A, Poser S, Kretzschmar H, Rietveld I, Mitrova E, de Pedro-Cuesta J, Martinez-Martin P, Glatzel M, Pocchiari A, Cooper S, Mackenzie J, van Dijl CM, Will RG: Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 1998, 351:1081-1085.
11. Ward HJ, Everington D, Cousins SN, Smith-Bathgate B, Gillies M, Murray K, Knight RS, Smith RG: Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008, 63:347-354.
12. Buckingham AJ, Meikle VH, Fraser H: Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968, 78:293-299.
13. Outram GW: The pathogenesis of scrapie in mice. In Slow Virus Diseases of Animals and Man. Edited by Kimberlin RH. Amsterdam: North-Holland Publishing Company; 1976:325-357.
14. Moreno CR, Lantier F, Lantier I, Sarradin P, Etnion JM: Detection of new quantitative trait loci for susceptibility to transmissible spongiform encephalopathies in mice. Genetics 2003, 163:2085-2091.
15. Pocchiari M, Turri J, Macchi G, Lenzi GL, Pocchiari M: Polypharmacology in a family with Creutzfeldt--Jakob disease. Ann Neurol 2008, 63:55-60.
16. Rolland Y, Spina D, Legrand-Poigny L, Pidoux B, Zerr I, Witek R, Willems P, Lacombe N, Herbrecht R,sevenier L, Lesage S, Prunet-F<hr>
38. Watts JC, Driessal B, Ng V, Yang J, Strome B, Horne P, Sy MS, Yoon L, Young R, Mastrandelo P, Bergeron C, Fraser PE, Carlson GA, Mount HT, Schmitt-Ulms G, Westaway D: The CNS glycoprotein Shado has PrP (C)-like protective properties and displays reduced levels in prion infections. EMBO J 2001; 20:4308-4305.

39. Xiang W, Wind O, Westner IM, Neumann M, Zerr I, Lederer RM, Kretzschmar HA: Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005; 58:242-257.

40. Minetti L, Pocchiari M: Cytochrome oxidase-2, protostaglandin e(2), and microglial activation in prion diseases. Int Rev Neurobiol 2007, 82:265-275.

41. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T: Differential expression of metalloproteinases in human prion diseases. Dement Geriatr Cogn Disord 2000, 11:251-262.

42. Ferrer I, Rivera R, Blanco R, Martí E: Expression of proteins linked to exocytosis and neurotransmission in patients with Creutzfeldt-Jakob disease. Neurobiol Dis 1999, 6:92-100.

43. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sanchez-Juan P, Mitrová E, Stoeck K, Bodemer M, Zerr I: Cerbrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 2009. doi: 10.1007/s00415-009-5163-x.

44. Brechn Jähn P, Steinacker J, Pecpek L, Kratzen H, Lehnen S, Jeske S, Mollenhauer B, Kretzschmar HA, Wittfang J, Otto M: Cerbrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 2008, 8:4357-4366.

45. Schmidt H, Otto M, Niedemann P, Pecpek L, Schröter A, Kretzschmar HA, Posser S: CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias. Dement Geriatr Cogn Disord 2004, 17:204-206.

46. Minetti L, Greco A, Cardone F, Puopolo M, Ladogana A, Almonti S, Cunningham C, Perry VH, Pocchiari M, Levi G: Increased brain synthesis of protostaglandin E2 and P2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000, 59:866-871.

47. Keshk S, Sassoon J, Knight R, Brown DR: Elevated manganese levels in brain and CNS in human prion disease. Mol Cell Neurosci 2008, 37:590-598.

48. Cordery RJ, MacManus D, Godbolt A, Rossor MN, Waldman AD: Short TE quantitative proton magnetic resonance spectroscopy in variant Creutzfeldt-Jakob disease. Eur Radiol 2006, 16:1692-1698.

49. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Stoeck K, Bodemer M, Zerr I: Cerbrospinal fluid protein (CSP) as a possible role in pathogenesis. Am J Pathol 2008, 173:1129-1142.

50. Biasini E, Massignan T, Fioriti L, Rossi V, Dossena S, Salmona M, Fortini G, Bonetto V, Chiesa R: Analysis of the calreticulin in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcium activity. Proteomics 2006, 6:2823-2834.

51. Miele G, Seeger H, Marino D, Eberhard J, Heitkemper M, Stoeck K, Basagni M, Knight R, Green A, Chianini F, Wuthrich RP, Hock C, Zerr I, Aguzzi A: Urinary alkaline antichymotrypsin: a biomarker of prion infection. PLoS ONE 2008, 3:e2337.

52. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC: A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003, 3:1495-1499.

53. Steinacker J, Mollenhauer B, Bibi M, Ceppek L, Esselmann H, Brechlin P, Lewczuk P, Posser S, Kretzschmar HA, Wildfang J, Trenkwalder C, Otto M: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004, 370:36-39.

54. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T: Regional brain metabolism abnormalities in inherited prion disease and asymmetric gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology 2006, 48:428-433.

55. Pagge TJ, Barclay GR, Stove GC, Stove G, Robinson MJ, Head MW, Ixions JW, Turner ML: Application of atomic dielectric resonance spectroscopy for the screening of blood samples from patients with clinical variant Creutzel-Jakob disease. J Transl Med 2007, 5:41.

56. Beekes M, Lasch P, Naumann D: Analytical applications of Fourier transform-infrared (FT-IR) spectroscopy in microbiology and prion research. Vet Microbiol 2007, 123:305-319.

57. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Stoeck K, Bodemer M, Zerr I: Cerbrospinal fluid protein (CSP) as a possible role in pathogenesis. Am J Pathol 2008, 173:1129-1142.

58. Brent J, Green A, Knight RS, Thompson J, Lee KH: Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neural 1996, 53:1233-1238.

59. Choe LH, Green A, Knight RS, Thompson J, Lee KH: Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis 2002, 23:2242-2246.

60. Völkl D, Zimmermann K, Zerr I, Lindner T, Bodemer M, Posser S, Schwarz HP: C-reactive protein and IL-6: new marker proteins for the diagnosis of CJD in plasma. Transfusion 2001, 41:1509-1514.

61. Sanchez JC, Guillaume E, Lesquier P, Allard L, Carrette O, Scherl A, Burgess J, Corthals GL, Burkhard PR, Hochstrasser DF, Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4:2229-2233.

62. Cepek L, Brechlin P, Steinerak M, Mollenhauer B, Klingebiel E, Bibi M, Kretzschmar HA, Wittfang J, Otto M: Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2007, 23:22-28.

63. Stafiej MK, Green A, Dick JP, Gawler J, Thompson J: Heightened intracerebral release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Neurology 1999, 52:1289-1291.

64. Stoeck K, Bodemer M, Zerr I: Protein and anti-inflammatory cytokines in the CSF of patients with Creutzfeld-Jakob disease. J Neuroimmunol 2006, 172:175-181.

65. Awerbuch G, Peterson P, Sandryk J: Elevated cerebrospinal fluid lactic acid levels in Creutzfeldt-Jakob disease. Int J Neurosci 1988, 42:1-5.

66. Bleich S, Kroop S, Degner D, Zerr I, Pitz J, Gleither CH, Otto M, Rüther E, Kretzschmar HA, Wildfang J, Kornhuber J, Posser S, Creutzfeldt-Jakob disease and oxidative stress. Acta Neural Scand 2000, 101:332-334.